SCHEMBL30822892

SCHEMBL30822892

Fc1cc2nc(Nc3cccc(C(F)(F)F)c3)[nH]c2cc1F

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC11 Q96DB2 1/20 0.60
HTT P42858 1/20 0.55
DYRK1A Q13627 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
RAF1 P04049 1/20 0.50
BRAF P15056 1/20 0.50
IDH2 P48735 3/20 0.49
KCNH2 Q12809 2/20 0.48
KIF11 P52732 3/20 0.48
AURKB Q96GD4 1/20 0.48
MAPT P10636 2/20 0.44
APP P05067 1/20 0.44
AURKA O14965 1/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30822932 0.86 DYRK1A (0.67) HTTDYRK1ADYRK1BRAF1BRAF
SCHEMBL30822913 0.86 HDAC11 (0.49) HDAC11HTTDYRK1ADYRK1BRAF1
SCHEMBL30822910 0.85 DYRK1A (0.51) HDAC11DYRK1ADYRK1BRAF1BRAF
SCHEMBL1998475 0.84 AKR1C3 (0.59) HTTDYRK1ADYRK1BRAF1BRAF
SCHEMBL30822891 0.82 HDAC11 (0.62) HDAC11RAF1BRAFMAPT
SCHEMBL30822902 0.79 RAF1 (0.60) HTTDYRK1ADYRK1BRAF1BRAF
SCHEMBL30822911 0.76 HTT (0.58) HTTRAF1BRAFIDH2KCNH2
SCHEMBL30822893 0.76 HTT (0.55) HTTDYRK1ADYRK1BIDH2KIF11
SCHEMBL4376917 0.76 BRAF (0.59) HTTDYRK1ADYRK1BRAF1BRAF
SCHEMBL30822901 0.75 DYRK1A (0.67) DYRK1ADYRK1BRAF1BRAFKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042743-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES COUNCIL SCIENT IND RES (IN) 2026-02-12 US claimed
EP-4565566-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) 2025-06-11 EP claimed
WO-2024028893-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2024-02-08 WO claimed
US-20260042743-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES COUNCIL SCIENT IND RES (IN) 2026-02-12 US disclosed
EP-4565566-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) 2025-06-11 EP disclosed
WO-2024028893-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042743-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES ACE2, SARS1, NR3C2 HDAC11 176/4885HTT 2192/4885DYRK1A 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.